NCT05673694View on ClinicalTrials.gov

To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

November 7, 2025

Study Completion Date

January 2, 2026

Conditions
Breast Cancer
Interventions
DRUG

EG017

According to the dosage group of the program, once a day.

Trial Locations (5)

100020

RECRUITING

Cancer Hospital of CAMS, Beijing

410000

RECRUITING

Hunan Cancer Hospital, Changsha

430000

RECRUITING

Wuhan Union Hospital, Wuhan

450000

RECRUITING

First Affiliated Hospital of Zhengzhou University, Zhengzhou

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY